OBJECTIVE: The aim of this study was to test a nonmyeloablative hematopoietic stem cell transplant regimen applicable to children with leukocyte adhesion deficiency (LAD) who have a histocompatible sibling donor by using the canine model of LAD, namely canine leukocyte adhesion deficiency or CLAD. METHODS: Thirteen CLAD pups received a hematopoietic stem cell transplant from a dog leukocyte antigen (DLA)-matched littermate donor after pretransplant nonmyeloablative conditioning with 200 cGy total-body irradiation and posttransplant immunosuppression with cyclosporine and mycophenolate mofetil. Donor chimerism following transplant was assessed by flow cytometry for the presence of donor CD18 peripheral blood leukocytes and leukocyte subsets. RESULTS: Eleven of the 13 transplanted animals achieved stable mixed donor chimerism and reversal of the severe CLAD phenotype without graft-vs-host disease. The level of donor chimerism ranged from 3.9 to 95.5% at 1 year following transplant. There was one early death 3 weeks after transplant from thrombocytopenia and hemorrhage, and one dog with donor microchimerism (0.5% CD18+ donor leukocytes) who had attenuation of the CLAD phenotype. CONCLUSION: These results demonstrate that a nonmyeloablative transplant regimen from a DLA-matched littermate donor leads to mixed chimerism and reversal of the severe disease phenotype in dogs with CLAD, and provides support for the use of this approach in children with LAD who possess a histocompatible sibling donor.
OBJECTIVE: The aim of this study was to test a nonmyeloablative hematopoietic stem cell transplant regimen applicable to children with leukocyte adhesion deficiency (LAD) who have a histocompatible sibling donor by using the canine model of LAD, namely canineleukocyte adhesion deficiency or CLAD. METHODS: Thirteen CLAD pups received a hematopoietic stem cell transplant from a dog leukocyte antigen (DLA)-matched littermate donor after pretransplant nonmyeloablative conditioning with 200 cGy total-body irradiation and posttransplant immunosuppression with cyclosporine and mycophenolate mofetil. Donor chimerism following transplant was assessed by flow cytometry for the presence of donorCD18 peripheral blood leukocytes and leukocyte subsets. RESULTS: Eleven of the 13 transplanted animals achieved stable mixed donor chimerism and reversal of the severe CLAD phenotype without graft-vs-host disease. The level of donor chimerism ranged from 3.9 to 95.5% at 1 year following transplant. There was one early death 3 weeks after transplant from thrombocytopenia and hemorrhage, and one dog with donor microchimerism (0.5% CD18+ donor leukocytes) who had attenuation of the CLAD phenotype. CONCLUSION: These results demonstrate that a nonmyeloablative transplant regimen from a DLA-matched littermate donor leads to mixed chimerism and reversal of the severe disease phenotype in dogs with CLAD, and provides support for the use of this approach in children with LAD who possess a histocompatible sibling donor.
Authors: Michael J Hunter; Huifen Zhao; Laura M Tuschong; Thomas R Bauer; Tanya H Burkholder; Derek A Persons; Dennis D Hickstein Journal: Hum Gene Ther Date: 2011-04-11 Impact factor: 5.695
Authors: Robert A Sokolic; Thomas R Bauer; Yu-Chen Gu; Mehreen Hai; Laura M Tuschong; Tanya Burkholder; Lyn Colenda; John Bacher; Matthew F Starost; Dennis D Hickstein Journal: Biol Blood Marrow Transplant Date: 2005-10 Impact factor: 5.742
Authors: Tanya H Burkholder; Lyn Colenda; Laura M Tuschong; Matthew F Starost; Thomas R Bauer; Dennis D Hickstein Journal: Blood Date: 2006-04-27 Impact factor: 22.113
Authors: Michael J Hunter; Laura M Tuschong; Cedar J Fowler; Thomas R Bauer; Tanya H Burkholder; Dennis D Hickstein Journal: Mol Ther Date: 2010-09-21 Impact factor: 11.454
Authors: Robert E Donahue; Laura Tuschong; Thomas R Bauer; Yu Ying Yau; Susan F Leitman; Dennis D Hickstein Journal: Blood Date: 2011-08-15 Impact factor: 22.113
Authors: Thomas R Bauer; Laura M Tuschong; Katherine R Calvo; Heather R Shive; Tanya H Burkholder; Eleanor K Karlsson; Robert R West; David W Russell; Dennis D Hickstein Journal: Mol Ther Date: 2013-03-26 Impact factor: 11.454
Authors: Thomas R Bauer; James M Allen; Mehreen Hai; Laura M Tuschong; Iram F Khan; Erik M Olson; Rima L Adler; Tanya H Burkholder; Yu-Chen Gu; David W Russell; Dennis D Hickstein Journal: Nat Med Date: 2007-12-23 Impact factor: 53.440
Authors: William H Peranteau; Todd E Heaton; Yu-Chen Gu; Susan W Volk; Thomas R Bauer; Keith Alcorn; Laura M Tuschong; Mark P Johnson; Dennis D Hickstein; Alan W Flake Journal: Biol Blood Marrow Transplant Date: 2009-03 Impact factor: 5.742